Obiltoxaximab

Administration

• Type: Monoclonal Antibody
• Dosage Forms: IV
• Routes of Administration: IV
• Common Trade Names: Anthim
• Info: Distributed directly to CDC

Adult Dosing

• Inhalation anthrax tx
  • <40 kg
    • 24 mg/kg IV x1
      • Premed with diphenhydramine
  • >40 kg
    • 16 mg/kg IV x1
      • Premed with diphenhydramine
• Inhalation anthrax prophylaxis, post-exposure
  • <40 kg
    • 24 mg/kg IV x1
      • Do not use as 1st line agent
      • Premed with diphenhydramine
  • >40 kg
    • 16 mg/kg IV x1
      • Do not use as 1st line agent
      • Premed with diphenhydramine

Pediatric Dosing

• Inhalation anthrax tx
  • <15 kg
    • 32 mg/kg IV x1
      • Premed with diphenhydramine
  • 16-40 kg
    • 24 mg/kg IV x1
      • Premed with diphenhydramine
  • >40 kg
    • 16 mg/kg IV x1
      • Premed with diphenhydramine
• Inhalation anthrax prophylaxis, post-exposure
  • <15 kg
    • 32 mg/kg IV x1
      • Do not use as 1st line agent
      • Premed with diphenhydramine
  • 16-40 kg
    • 24 mg/kg IV x1
      • Do not use as 1st line agent
      • Premed with diphenhydramine
  • >40 kg
    • 16 mg/kg IV x1
      • Do not use as 1st line agent
      • Premed with diphenhydramine

Special Populations

• Pregnancy Rating: C; Benefits outweigh risks during pregnancy.
• Lactation risk: L3; Safety unknown

Renal Dosing

• Adult: Not defined
• Pediatric: Not defined

Hepatic Dosing

• Adult: Not defined
• Pediatric: Not defined

Contraindications

• Allergy to class/drug

Adverse Reactions

Serious

• Hypersensitivity reaction
• Anaphylaxis

Common

• Hypersensitivity reaction
• Headache
• URI
• Pruritus
• Cough
• Injection site reaction
• Nasal congestion
• Urticaria
• Extremity pain

Pharmacology

• Half-life: 15-23 Days
• Metabolism: Other; CYP450: unknown
• Excretion: Other

Mechanism of Action

• A monoclonal antibody that binds to anthrax toxin to prevent lethal and edema factors' intracellular entry and neutralizes toxic effects.

See Also

• Bioterrorism
• Anthrax